Marginal zone lymphoma - historical
Jump to navigation
Jump to search
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? Please go to the main MZL regimen page to find other regimens.
1 regimens on this page
1 variants on this page
|
Relapsed or refractory
Umbralisib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Fowler et al. 2021 (UNITY-NHL) | 2017-2018 | Phase 2b (RT) |
Targeted therapy
- Umbralisib (Ukoniq) 800 mg PO once per day on days 1 to 28, taken with food
28-day cycles
References
- UNITY-NHL: Fowler NH, Samaniego F, Jurczak W, Ghosh N, Derenzini E, Reeves JA, Knopińska-Posłuszny W, Cheah CY, Phillips T, Lech-Maranda E, Cheson BD, Caimi PF, Grosicki S, Leslie LA, Chavez JC, Fonseca G, Babu S, Hodson DJ, Shao SH, Burke JM, Sharman JP, Law JY, Pagel JM, Miskin HP, Sportelli P, O'Connor OA, Weiss MS, Zinzani PL. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2021 May 20;39(15):1609-1618. Epub 2021 Mar 8. link to original article link to PMC article contains dosing details in manuscript PubMed NCT02793583